Your coach will guide the progression
All of the known GLPs produce clinically significant reductions in hemoglobin A1c levels
In particular: NICE Technology Appraisal TA875 provides a positive recommendation for semaglutide (Wegovy) for chronic weight management in adults meeting specific criteria (BMI 35 kg/m with at least one weight-related comorbidity, or BMI 3034.9 kg/m in certain circumstances), when used within a specialist weight management service
The five qualifying conditions The five qualifying conditions for the NHS pathway under NICE TA1026 are 4 : Type 2 diabetes High blood pressure (hypertension) Cardiovascular disease (previous heart attack, stroke, angina, or coronary procedure) High cholesterol or dyslipidaemia Obstructive sleep apnoea For the private route, the Mounjaro and Wegovy product licences accept any one of these, plus prediabetes (an HbA1c blood-sugar reading between 42 and 47 mmol/mol) 1,2
Retatrutide what is it, and when might it emerge
Therefore, DPP-4 inhibitors extend the half-life of endogenous GLP-1 lead to a 2threefold elevation of endogenous GLP-1 concentration, and provide beneficial effects in T2DM [110, 111]
